Pfizer was the top innovator in the clinical trial operations sector in the latest quarter. The company filed 22 related patents in the three months ending February. That was up from 12 over the same period in 2021.
It was followed by Johnson & Johnson with nine patent applications, and Bayer AG (6 applications).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPfizer has recently ramped up R&D in cloud. It saw growth of 45.5% in related patent applications in the three months ending February compared to the same period in 2021 - the highest percentage growth out of all companies tracked with more than 10 quarterly patents in the clinical trial operations sector.
Yet research and innovation in cloud in the clinical trial operations sector has declined in the last year.
The most recent figures show that the number of related patent applications in the industry stood at 17 in the three months ending February - down from 18 over the same period in 2021.
Figures for patent grants related to followed a similar pattern to filings - shrinking from seven in the three months ending February 2021 to two in the same period in 2022.
The figures are compiled by GlobalData, who track patent filings and grants from official offices around the world. Using textual analysis, as well as official patent classifications, these patents are grouped into key thematic areas, and linked to key companies across various industries.
is one of the key areas tracked by GlobalData. It has been identified as being a key disruptive force facing companies in the coming years, and is one of the areas that companies investing resources in now are expected to reap rewards from.